Novel p53 therapies for head and neck cancer
Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human pa...
Saved in:
Main Authors: | Mario R. Castellanos, Quintin Pan |
---|---|
Format: | article |
Language: | EN |
Published: |
KeAi Communications Co., Ltd.
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/7f96e30f0f9547dda9dba2c79df9c3a2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel therapeutics and emerging technologies in head and neck cancer
by: Theodoros N. Teknos, M.D.
Published: (2016) -
The current status of oncolytic viral therapy for head and neck cancer
by: Matthew O. Old, et al.
Published: (2016) -
Circulating tumor cells in head and neck cancer: A review
by: Kyle P. McMullen, et al.
Published: (2016) -
The effect of treatment package time in head and neck cancer patients treated with adjuvant radiotherapy and concurrent systemic therapy
by: Ahmed I. Ghanem, et al.
Published: (2019) -
Intra-tumor heterogeneity in head and neck cancer and its clinical implications
by: Edmund A. Mroz, et al.
Published: (2016)